• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Altoida Raises $6.3M for Early Detection of Alzheimer’s Using AI & Augmented Reality

by Fred Pennic 05/31/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Altoida Raises $6.3M for Early Detection of Alzheimer’s Using AI & Augmented Reality

Altoida Inc., a digital health company using digital biomarkers to drive better clinical outcomes for brain diseases has raised $6.3M in Series A funding led by M Ventures, the corporate venture capital arm of the science and technology company Merck KGaA, Darmstadt, Germany. The round also includes participation from Grey Sky Venture Partners, VI Partners AG, Alpana Ventures, and FYRFLY Venture Partners.

Taking Aim at the Alzheimer’s Disease Epidemic

The number of people living with Alzheimer’s disease is rapidly growing. In 2019 alone, Alzheimer’s disease and other dementias will cost the nation $290 billion. By 2050, these costs could rise as high as $1.1 trillion. Yet, research shows 1 in 3 dementia cases are preventable if diagnosed before permanent and irreversible brain damage occurs.

Digital Biomarkers Platform

Founded in 2016 by a team of neuroscientists, physicians, and computer scientists, Altoida offers an FDA and CE Mark-cleared medical device and brain health data platform to support early detection of Alzheimer’s disease up to ten years prior to onset – with up to 94% accuracy.  Unlike other detection solutions that collect passive data or only focus on a single behavior, Altoida collects a wide range of ‘active’ digital biomarkers as the patient is moving and completing tasks. They’ve amassed a vast dataset that not only helps them diagnose Alzheimer’s with unprecedented accuracy, but is tremendously valuable for ongoing research.

Altoida’s digital biomarkers harness advances in technology to detect brain changes early in the disease process, helping to accelerate early diagnosis for better clinical outcomes. Using an iPad or a Tablet accelerometer, gyroscope and touch screen sensors, Altoida is able to detect “micro-errors” as both a prognostic and diagnostic digital biomarker.  The result is that medical professionals are able to detect Alzheimer’s disease in patients 62+ years old between six and ten years prior to the onset of symptoms – and before irreversible damage occurs.

Collected over the last 12 years, Altoida also offers its comprehensive digital biomarker dataset to researchers and major pharmaceutical companies who want to leverage pre-symptomatic data to enhance both treatment and drug R&D. Today, the company is working on two joint research collaborations with large pharmaceutical companies in both the United States and Japan. The new capital will be used to further expand Altoida’s global presence with an immediate focus on commercialization activities in the US and EU markets.

“While we know that early detection of Alzheimer’s is the key and leads to better outcomes, only 16% of seniors today receive regular assessments in the US, and this situation becomes more critical as we look at other geographic regions,” said Dr. Richard Fischer, Founder & CEO at Altoida. “Today’s diagnosis methods are either outdated, costly and invasive or highly nuanced. We are taking aim at this acute problem with a fast, fun, accurate and scalable AI-driven solution that collects digital biomarkers to predict the onset of Alzheimer’s as early as ten years before symptoms appear – we like to call them “micro errors”. Our software or app is designed to be used by a wide range of healthcare professionals, from primary care physicians (GP’s) to neurologists to insurance companies, in order to make early detection accessible to more people around the world with the goal of significantly delaying the onset of MCI due to AD – and resulting in an overall cost reduction.”

Altoida "AMD" Video from Richard Fischer on Vimeo.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Biomarker-Guided Drug Development, Biomarkers, Digital Biomarkers

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |